Global Moxifloxacin API Market

Moxifloxacin API Market Insights

The Moxifloxacin API Market will have an extremely moderate CAGR appraisal of 1.2% from 2020 to 2026. Being a fluoroquinolone antibiotic, this drug treats bacterial infection. Moxifloxacin is utilized to treat various sorts of bacterial infection/ diseases of the skin, sinuses, lungs, or stomach. Some bacterial infections ultimately cause serious or chronic bronchitis, sinusitis, Pneumonia, and other related skin or superficial infection. Hence, rising cases of major ailments like bronchitis and pneumonia will support the growth of the market from 2020 to 2026. However, besides the FDA-approved indication, Moxifloxacin has gathered the interest of researchers and healthcare providers during the COVID-19 pandemic. The researchers have concluded that Moxifloxacin could be useful in lessening viral burden and irritation during SARS-CoV2 disease, particularly for contrarily managing deadly aggravation in serious COVID-19 patients. Hence, this market will have a moderate growth rate amid and post COVID-19 pandemic.

Moxifloxacin API Market: By Type for Drug

As per the type of drugs available, the market can be segmented into the brand and generic Moxifloxacin drugs.  The generic version of Moxifloxacin API will be both, fastest and largest shareholders as compared to the branded version of this drug.

Moxifloxacin API Market: By Route of Administration

The market can be foreseen as oral administration, intravenous administration, and ophthalmic route administration. Oral administration is the most preferred and prescribed route of administration and hence will be the largest segment in the Moxifloxacin API market.

Moxifloxacin API Market: By Indication

Bronchitis, Pneumonia, Sinusitis, Pelvic Inflammatory Disease, Intra-Abdominal Infections, and Skin & Eye Infections are the major application segments of fluoroquinolone antibiotic namely Moxifloxacin API. As of 2017, more than 2.56 million people died of Pneumonia especially in the developing and underdeveloped countries including Southeast Asian countries and the Sub-Saharan African region. Hence considering the high prevalence of this disease makes it the largest market segment from 2020 to 2026

Moxifloxacin API Market: By Region

As per the geographical analysis, the APAC region will foresee a rise in its growth improvement due to increasing cases of Bronchitis and Pneumonia. Around 99% of deaths recorded in some parts of the Asian region are mainly due to some form of bacterial infection of the internal organs and chronic bronchitis cases. However, based on the number of prescription data, the US stands first in the market in terms of value sales and market share.

Moxifloxacin API Market Share and Competitor Analysis

Major companies in the market are Cayman, Rivopharm, Actavis (TEVA), BOC Sciences, Bayer, MERCK, Tecoland, Allergan, NIVIKA Chemo Pharma, Aurobindo, Orex Pharma, Ningbo Distant Chemicals Co., Ltd., JINLAN Pharm-Drugs Technology Co., Ltd., Hetero Drugs, Nosch Labs, Nueland Labs, Chongqing Huapont, Menovo, Dr. Reddy's, Mylan, Macleods Pharma, Unimark Remedies Ltd., Vital Laboratories, GVK Bioscience Pvt Ltd, and HEC Pharma among others.

Please note: This is not an exhaustive list of companies profiled in the report.

In September 2020, the American Society of Cataract and Refractive Surgery, The American Academy of Ophthalmology, the American Association for Pediatric Ophthalmology and Strabismus, the American Glaucoma Society, the Retina Society, the American Society of Retina Specialists, the Cornea Society, and the Macula Society together have requested or raised a plea to US FDA, to reconsider the unlisting of Moxifloxacin for ophthalmic infection treatment and rethink on the removal of the drug from 503B bulk drug list.

Check the Press Release on Global Moxifloxacin API Market Report